MDR TB AND CASE STUDIES
|
|
- Duane Goodman
- 5 years ago
- Views:
Transcription
1 MDR TB AND CASE STUDIES Chris Keh, MD Director, TB Prevention and Control Program, SFDPH HS Assistant Clinical Professor, Infectious Diseases, UCSF Seattle, CITC Clinical Intensive June 15, 2018 Slide 2 Objectives Explain factors which could lead to increased multidrug-resistant tuberculosis and how best to prevent and decrease the possibilities Describe the rationale for the multidrug-resistant tuberculosis treatment guidelines and apply them to achieve optimal patient outcomes 1
2 Slide 3 Disclosures I will be presenting information on investigational or off-label use of second / third line TB drugs (e.g. Amikacin, Delamanid, Linezolid, Amoxicillin-clavulanate, Kanamycin, Meropenem, Augmentin, Fluoroquinolones, Rifabutin, Clofazimine, Imipenem). Objectives 4 MDR TB epidemiology (US) / Background Molecular diagnostics / DST MDR Treatment Infection Control Summary 2
3 Drug-Resistant TB: Definitions Mono-resistant: Resistance to a single drug Poly-resistant: Resistance to more than one drug, but not the combination of isoniazid and rifampicin Multidrug-resistant (MDR): Resistance to at least isoniazid and rifampicin Extensively drug-resistant (XDR): MDR + resistance to fluoroquinolones and 1 of the 3 injectable drugs (amikacin, kanamycin, capreomycin) Primary Anti TB Drug Resistance, United States, * Resistant (%) Isoniazid MDR TB Year INH resistance = 8.7% MDR TB = 1.2% * As of June 21, Note: Based on initial isolates from persons with no prior history of TB; multidrug resistant TB (MDR TB) is defined as resistance to at least isoniazid and rifampin. 3
4 Primary MDR TB, United States, * No. of cases Number of cases Percentage of total cases 78 total cases reported in 2016 (1.2% of cases) 90% of primary MDR cases attributed to non U.S. born 1 case of XDR reported in Year Percentage * As of June 21, 2017 Case 1 Case: Gisela Schecter, MD 21-year-old Filipina woman with Type I DM recently emigrated from the Philippines No TB screening at the time of immigration History of treatment for TB with INH +/- RIF as a child and, more recently, with INH, RIF, PZA and EMB given by SAT last year Presented with cough x 5 months, progressive SOB/DOE x 6 weeks, pleuritic chest pain and fever to 101 degrees 4
5 Case 1 Case: Gisela Schecter, MD Case 1 Case: Gisela Schecter, MD 5
6 Case 1 Case: Gisela Schecter, MD Do you suspect DR? Why? 21-year-old Filipina woman with Type I DM recently emigrated from the Philippines No TB screening at the time of immigration History of treatment for TB with INH +/- RIF as a child and, more recently, with INH, RIF, PZA and EMB given by SAT last year Presented with cough x 5 months, progressive SOB/DOE x 6 weeks, pleuritic chest pain and fever to 101 degrees 6
7 Frequency of Random Naturally Occurring Resistance Mutations INH = 3.5 x 10-6 RIF = 1.2 x 10-8 EMB = 3.1 x 10-5 PZA = 1.0 x 10-5 Strep = 3.8 x 10-6 INH+RIF = 4.2 x (Approximately 10 7 to 10 9 organisms per cavity) Estimated global incidence and proportion of MDR among TB cases Estimated: 490,000 new cases of MDR 4.1% of all new cases and 19% of previously treated cases have MDR (or R- Resistance) Of notified cases almost half are from India, China, and the Russian Federation WHO 2016 report Share of Global Incidence (%) 7
8 Most Important Predictors for Drug Resistance Previous episode(s) of TB treatment Worsening clinical and/or radiographic findings while on TB therapy Origin from, history of residence in, or frequent travel to a region or country with a high prevalence of drug-resistant TB Exposure to an individual with known (or highly suspected) infectious drug-resistant TB, or exposure to individuals in congregate settings where drug resistance has been documented Drug Resistant TB: Survival Guide, 3 rd edition Slide 15 Additional Factors for Clinical Suspicion Presence of RIF resistance predicts MDR (Rifampin monoresistance is rare) HIV+ (higher incidence of RIF mono-resistance) Slide 16 Drug Resistant TB: Survival Guide, 3 rd edition 8
9 Objectives 17 MDR TB epidemiology (US) / Background Molecular diagnostics / DST MDR Treatment Infection Control Summary Case 2: 31 yo M with HIV and cough x 1 yr 18 Hemoptysis, 30 kg weight loss, fatigue Has been living in Thailand for years CD4=280, VL ND, on ART Presented to ER on 5/3 Sputum smear = numerous AFB on 5/4 GeneXpert = POSITIVE MTB, RIF resistance DETECTED on 5/4 Active TB regimen (expanded) started 5/4 9
10 Case 3: 45 yo Chinese M with dry cough x 1 yr Leg weakness and weight loss Moved to US 7 years ago with hx IVDU New dx of DM (HbA1c 13.6%) and HCV with liver mass/hcc Presented to ER on 6/3 Sputum smear = numerous AFB on 6/4 GeneXpert = POSITIVE MTB, RIF resistance DETECTED on 6/4 Active TB regimen (expanded) started 6/4 19 Case 4: 43 yo M recently immigrated from Philippines Severe back pain, fatigue, loss of appetite, weight loss Dx with Pott s Diseases C7-S1 based on FNA that was smear neg, culture pos Started on RIPE, but then PZA stopped due to uric acid elevation After 2 months of treatment, worsening back pain Repeat MRI with concern for progression of disease 20 What are your questions? 10
11 Rapid Molecular Diagnostics NAAT/Beacon (GeneXpert) Sequencing (Molecular Detection of Drug Resistance MDDR, CDC) Xpert MTB/RIF Test Performance 22 Sensitivity Specificity Smear pos. TB 95 98% Smear neg. TB 60 72% 99% Rifampin R 98 99% % NEJM 361:1005, 2010; Am J Crit Care Med 184:132, 2011 Provides both MTB identification and detection of RIF resistance (rpob) RIF mono resistance is rare; thus detection of RIF resistance on genexpert is a red flag for possible MDR. Run time ~2 hours May give false negative if low DNA copies May yield no results if inhibitors present 11
12 23 Xpert MTB/RIF Report MTB DETECTED or NOT DETECTED Rif Resistance DETECTED or NOT DETECTED Not useful to follow once positive (DNA can be detected even after completion of adequate tx). Rapid Molecular Testing to Identify Drug Resistance Sequencing ( MDDR at CDC) Short turnaround time Screen for resistance: INH, RIF, EMB, PZA, FQ, injectable Reports specific mutation Smear positive sputum or culture Requested by/through state public health lab 12
13 Slide 25 MDDR submission criteria High-risk of RMP resistance or MDR TB Known RMP resistance (by rapid test or by culture-based DST) High public health impact (e.g., daycare workers, nurses) Adverse reactions to critical anti-tb drug (e.g.,allergy to RMP) Mixed or non-viable cultures Isolates which fail to grow in DST medium Performance characteristics of MDDR by Drug Slide 26 Drug Locus or Loci Sensitivity (%) Specificity (%) examined RMP rpob INH inha + katg FQ gyra KAN rrs + eis AMK rrs CAP rrs + tlya EMB embb PCA pnca Additional resource: Helpful table DR mutations: Survival Guide v3 pages
14 Rapid Molecular Testing- Benefit Short turnaround time (compared to phenotypic methods) Earlier initiation of effective tx Decreased period of infectiousness Improved pt outcome Earlier involvement of MDR expert Earlier request for 1 st /2 nd line susceptibilities High stakes setting MDR suspect Pregnancy HIV/immunocompromised Do Not Board decisions Public health settings (shelter, congregate, schools) Rapid Molecular Testing- points to consider False negatives may occur Inhibitors Low DNA load NTM/mixed Results can help to guide early changes in treatment, but must always be confirmed with phenotypic data (susceptibility testing) 14
15 Slide 29 Remember! Drug Susceptibility Testing (DST) Smear and culture (drug susceptibility testing) remain the gold standard 1 st -line DST at local / commercial labs Many states perform basic 2 nd -line DST CDC performs expanded 2 nd -line DST Slide 30 CDC- Drug Susceptibility Testing (DST) Isoniazid Rifampin Ethambutol Ciprofloxacin Ofloxacin Streptomycin Kanamycin Capreomycin Amikacin Rifabutin Ethionamide Para-aminosalicylic acid (PAS) Pyrazinamide* Bedaquiline** *Tested by MGIT 960 (all others indirect proportion) **Available upon request 15
16 Other- Drug Susceptibility Testing (DST) (i.e. may need to send to commercial lab) Linezolid Cycloserine Slide 31 Objectives 32 MDR TB epidemiology (US) / Background Molecular diagnostics / DST MDR Treatment Infection Control Summary 16
17 MDR Treatment- General Principles Seek expert consultation Never add a single drug to a failing regimen When choosing drugs: Consider cross-resistance Consider side-effects Avoid drugs used previously to treat patient s TB Slide 33 Drug Resistant TB: Survival Guide, 3 rd edition CITC Warmline Consultation Curry International Tuberculosis Center NOTB OR
18 Building a Regimen for MDR-TB (1) STEP 1 Begin with any firstline agents to which the isolate is susceptible Use any available First line drugs One of these Fluoroquinolone One of these Injectable agents Add a fluoroquinolone and an injectable drug based on susceptibilities Pyrazinamide Ethambutol Levofloxacin Moxifloxacin Capreomycin Kanamycin Amikacin Streptomycin* * Only use if documented sensitivity Drug Resistant TB: Survival Guide, 3 rd edition Building a Regimen for MDR-TB (2) STEP 2 Add second line drugs until you have four to six drugs to which the isolate is susceptible (and preferably which have not been used to treat the patient previously) Pick one or more of these Oral second line drugs Cycloserine Ethionamide PAS Linezolid Drug Resistant TB: Survival Guide, 3 rd edition 18
19 Building a Regimen for MDR-TB (3) STEP 3 If there are not 4 6 drugs available in the above categories, consider third line drugs in consultation with an expert Bedaquiline Delamanid Clofazimine Consider use of these Third line drugs Amoxicillin/ Clavulanate Meropenem / Clavulanate Imipenem Clarithromycin High dose INH Drug Resistant TB: Survival Guide, 3 rd edition Treatment Duration 2003 ATS/CDC/IDSA guidelines: mo WHO 2016 Intensive phase at least 8 months Total duration at least 20 months (if no prior rx for MDR; if prior MDR rx at least 24 months) Allows use of short 9-12 month regimen for specific circumstances Survival Guide Expert consensus: Utilize culture conversion to help guide minimum duration within U.S. high resource setting Intensive phase: at least 6 mo beyond culture conversion for use of injectable agent Total duration: at least 18 months beyond culture conversion 19
20 Short course Bangladesh regimen (9-12 mo) Intensive phase (4-6 mo): Kanamycin, gatifloxacin, prothionimide, high-dose INH, clofazamine, ethambutol, PZA Continuation (5 mo): gatifloxacin, clofazamine, ethambutol, PZA : Treatment success 84.5% (n=515) KJM Aung et al. Int J Tuberc Lung Dis 2014 ;18(10) Ongoing multi-country observational study Separate STREAM trial [randomized 9 mo (except uses Moxi) vs standardized regimen]; adds BDQ arm (6 and 9 month regimens) Bedaquiline (Janssen) Class diarylquinoline Mechanism of action - novel ATP synthase inhibitor Activity In vitro bactericidal (replicating and dormant) Animal bactericidal and sterilizing activity Early bactericidal activity similar to isoniazid or rifampicin 20
21 CDC Provisional Guidelines: Bedaquiline When an effective treatment regimen cannot be provided: BDQ may be used for 24 weeks of treatment in adults with laboratory-confirmed pulmonary MDR-TB BDQ may by used on a case-by-case basis in children, HIV infected persons, pregnant women, extrapulmonary MDR-TB, and patients with comorbid conditions BDQ may be used on a case-by-case basis for durations longer than 24 weeks (5.5 mo. ½ life) DOSE: 400 mg once daily for 2 weeks, then 200 mg three times a week for 22 weeks, taken with food CDC MMWR 2013;62;1 12 CDC Provisional Guidelines: Bedaquiline No dose adjustment with mild/mod renal impairment Drug interactions metabolized through CYP3A Hepatotoxicity AST, ALT, bilirubin, alkaline phosphatase monthly Cardiac toxicity Baseline ECG and then 2, 12, and 24 weeks Baseline K, Ca, Mg levels Discontinue if QTcF >500 ms or ventricular arrthymias CDC MMWR 2013;62;
22 Common Adverse Effects G.I. complaints Hepatotoxicity (early symptoms are anorexia and malaise, then abdominal pain, vomiting, jaundice) Ethionamide Cycloserine PAS Fluoroquinolones Clofazimine Rifabutin INH Rifampicin/rifabutin Ethionamide PZA PAS Fluoroquinolones Common Adverse Effects Peripheral neuropathy Rash Headache Seizures INH Ethionamide Cycloserine Linezolid Ethambutol Fluoroquinolones All Fluoroquinolones Isoniazid Cycloserine Ethionamide Ethambutol Cycloserine 22
23 Common Adverse Effects Hypothyroidism Hearing loss, Vestibular toxicity Behavioral changes Visual changes Renal failure Hypokalemia, Hypomagnesemia Ethionamide, PAS Aminoglycosides, Capreomycin Cycloserine, Ethionamide, Isoniazid, Fluoroquinolones Ethambutol, Rifabutin, Isoniazid, Linezolid Aminoglycosides, Capreomycin Just one example of the tools needed Slide 46 GI complaints (very very very common)- Drug ramping (CS, PAS, ETA) Supportive care (H2 blockers, PPI, antacids) Split dosing (for some meds), QHS dosing, admin with food Anti-emetics, pre-medication, benzodiazepines Crushing, cutting, liquids, capsules surrounding tablets Alternative: ginger, sea-band, lemon heads, other Switching to IV formulation PEG, J-tube 23
24 Slide 47 Additional monitoring (drug dependent) EKG (bedaquiline, fluoroquinolones high dose or combined with other QTc prologing agents) Drug levels (e.g. aminoglycosides, PAS, cycloserine, ethionamide) Audiology (aminoglycosides)- monthly until 1 month post-d/c of injectable TSH, pregnancy test, PSQ-9, vestibular exam, visual acuity/ishihara Drug-drug interactions- anti-depressants, QTc prolonging agents Decision of IM vs IV Case 1- What would you start? 21-year-old Filipina woman with Type I DM recently emigrated from the Philippines History of treatment for TB with INH +/- RIF as a child and, more recently, with INH, RIF, PZA and EMB given by SAT last year RIPE + Moxi Molecular testing shows resistance to RIF/INH MDR consultation: Start EMB, PZA, Moxi, PAS, Cycloserine, Amikacin 24
25 Case 2- What would you start? Hemoptysis, 30 kg weight loss, fatigue Has been living in Thailand for years CD4=280, VL ND, on ART Sputum smear = numerous AFB on 5/4 GeneXpert = POSITIVE MTB, RIF resistance DETECTED on 5/4 Initial start: RIPE + FQ + amikacin + linezolid After PSQ, MDDR, DST adjusted to: EMB, PZA, FQ, amikacin, linezolid, bedaquiline (+/- PAS) 49 Case 3: What would you start? Leg weakness and weight loss Moved to US 7 years ago with hx IVDU New dx of DM (HbA1c 13.6%) and HCV with liver mass/hcc Sputum smear = numerous AFB on 6/4 GeneXpert = POSITIVE MTB, RIF resistance DETECTED on 6/4 Initial start: RIPE + FQ + amikacin + linezolid After PSQ, MDDR, DST adjusted to: PZA,FQ, amikacin, linezolid, bedaquiline 50 25
26 Case 4: 43 yo M recently immigrated from Philippines Severe back pain, fatigue, loss of appetite, weight loss Dx with Pott s Diseases C7-S1 based on FNA that was smear neg, culture pos Started on RIPE, but then PZA stopped due to uric acid elevation After 2 months of treatment, worsening back pain Repeat MRI with concern for progression of disease 51 Initial start: RIPE + linezolid + FQ + injectable After PSQ, MDDR, DST adjusted to: FQ, amikacin, linezolid, PAS, cycloserine Objectives 52 MDR TB epidemiology (US) / Background Molecular diagnostics / DST MDR Treatment Infection Control Summary 26
27 Slide 53 Infection Control considerations Drug-resistant TB is similar in transmissibility to drug-susceptible TB (WHO 2014) Because MDR-TB transmission has more serious consequences, criteria for release from isolation is more conservative, in particular for high-risk settings. Some experts would consider MDR-TB patients potentially infectious as long as their sputum cultures remain positive. Example criteria for smear positive: Drug-susceptible TB: smear conversion x 3 AND at least 14 days of treatment AND clinical improvement MDR TB: smear conversion x 3 (no subsequent positive smear) AND at least 14 days of treatment AND clinical improvement AND at least 2 consecutive negative sputum cultures without subsequent positive * CTCA/CDPH Criteria for Infectiousness and Placement in High and Lower Risk Settings Objectives 54 MDR TB epidemiology (US) / Background Molecular diagnostics / DST MDR Treatment Infection Control Summary 27
28 Summary High-risk MDR: Action Steps Obtain rapid molecular test for drug sensitivity E.g. Xpert RIF/MTB (local), MDDR (CDC) Order both first (local) and second-line (state or CDC) DST Consider initiation of expanded regimen Never add a single drug to a failing regimen Consult your friendly neighborhood MDR expert Summary: MDR Pearls Slide 56 DOT should be performed (7 days / wk ideal, 5 days / wk acceptable) Use a case management / tracking tool; drug-o-grams can be your friend TB treatment requires multi-disciplinary collaboration for optimal care! Divide and conquer: Nursing, TB case managers Physicians (pulmonary / ID, hospitalist, primary care, TB control) Infection control Social workers, contact investigators, community outreach workers Specialty care: e.g ophtho, neurology, audiology, HIV, endocrine, etc. 28
29 Slide 57 Snapshot comparison Drug susceptible TB MDR TB Average treatment duration = 6 months Average treatment duration = =18 24 months or more Average cost = 18,000 Average cost = 134,000 (MDR) 494,000 (XDR) Average isolation = 5 14 days minimum Average isolation = 2 months minimum (in many cases may be longer) (in many cases may be longer) Average number of drugs used initially = 4 Average number of drugs used initially = 6 8 Common complications: hepatitis, rash, GI upset Many more complications: nephrotoxicity, peripheral neuropathy, optic neuritis, ++ GI upset, vestibular/ototoxicity, bone marrow suppression, hepatotoxicity, depression, CNS toxicity 58 Helpful resources Treatment Guidelines: CDC/ATS/IDSA, Treatment of Tuberculosis, 2016 (MDR guideline in progress) Regional Training and Medical Consultation Centers (RTMCC), Drug-Resistant Tuberculosis: A Survival Guide for Clinicians, Curry Center (2016) WHO 2016 Guidelines Med side effects: Tuberculosis Drug Information Guide, Curry Center 29
30 59 THANK YOU! Special thanks to Lisa Chen, MD for slides and guidance Design by Mehroz Baig v
TB Grand Rounds. MDR-TB: Management of Adverse Drug Reactions. Reynard J. McDonald, M.D. September 18, Patient History
TB Grand Rounds MDR-TB: Management of Adverse Drug Reactions Reynard J. McDonald, M.D. September 18, 2007 Patient History This 30 y/o H/M was born in Ecuador and immigrated to the US in 2001 On 11-22-05
More informationClinical Management : DR-TB
Clinical Management : DR-TB Charoen Chuchottaworn MD., Senior Medical Advisor, Central Chest Institute of Thailand, Department of Medical Services, MoPH. Tuberculosis Classification Drug susceptible TB
More informationDrug resistant TB: Lisa Chen, MD University of California, San Francisco Curry Interna:onal TB Center Sea=le, June 2016
Drug resistant TB: Lisa Chen, MD University of California, San Francisco Curry Interna:onal TB Center Sea=le, June 2016 Drug- Resistant TB: De1initions Mono- resistant: Resistance to a single drug Poly-
More informationPractical. Walk through New Survival Guide
Many faces of TB: Drug resistant it ttbs Survival lgid Guide v3 P B L Ch G Sh t L T P. Barry, L. Chen, G. Schecter, L. True Curry International TB Center/CTCA April 20, 2016 Real case Practical Walk through
More informationMultidrug-resistant Tuberculosis. Charles L. Daley, MD National Jewish Health Chair, Global GLC, WHO and Stop TB Partnership
Multidrug-resistant Tuberculosis Charles L. Daley, MD National Jewish Health Chair, Global GLC, WHO and Stop TB Partnership Disclosures World Health Organization Chair, Global GLC Otsuka Chair, Data Monitoring
More informationDrug-resistant TB therapy: the future is now
Drug-resistant TB therapy: the future is now Gary Maartens Thanks to Francesca Conradie for sharing slides Division of Clinical Pharmacology UNIVERSITY OF CAPE TOWN IYUNIVESITHI YASEKAPA UNIVERSITEIT VAN
More informationMDR/XDR TB. Barbara Seaworth, MD, FIDSA, FACP October 27, TB Intensive October 24 27, 2017 San Antonio, TX
MDR/XDR TB Barbara Seaworth, MD, FIDSA, FACP October 27, 2017 TB Intensive October 24 27, 2017 San Antonio, TX EXCELLENCE EXPERTISE INNOVATION Barbara Seaworth, MD, FIDSA, FACP, has the following disclosures
More informationMultidrug-resistant Tuberculosis
Multidrug-resistant Tuberculosis Pennan Barry, MD, MPH California MDR TB Consult Service Surveillance and Epidemiology Section Curry International Tuberculosis Center Clinical Intensive September 2016
More informationTreatment of Multidrug-resistant Tuberculosis (MDR-TB)
Treatment of Multidrug-resistant Tuberculosis (MDR-TB) 2006 2008 2011 2013 2014 2016 2019 Charles L. Daley, MD National Jewish Health University of Colorado Disclosures Research grant Insmed: Phase II
More informationMultidrug resistant Tuberculosis
Multidrug resistant Tuberculosis Pennan Barry, MD, MPH California MDR TB Consult Service Surveillance and Epidemiology Section Curry International Tuberculosis Center Clinical Intensive October 018 Objectives
More informationTB Intensive San Antonio, Texas
TB Intensive San Antonio, Texas April 6-8, 2011 Drug Resistant TB Barbara Seaworth, MD Thursday April 7, 2011 Barbara Seaworth, MD has the following disclosures to make: Has received research funding from
More informationTreatment of Drug Resistant TB
Treatment of Drug Resistant TB Diana M. Nilsen RN, MD Bureau of TB Control New York City Department of Health & Mental Hygiene Objectives Definition of other drug resistant (ODR), multiple drug resistant
More informationStrategies for Successful Treatment of Drug Resistant Tuberculosis in the U.S.
Strategies for Successful Treatment of Drug Resistant Tuberculosis in the U.S. Barbara J. Seaworth, M.D. Professor of Medicine University of Texas Health Science Center, Tyler Medical Director, Heartland
More informationChallenges to treat MDR TB
Challenges to treat MDR TB Manfred Danilovits Tartu University Hospital, Estonian NTP Program 2nd European Advanced Course in Clinical Tuberculosis 22-24 September 2014, Amsterdam MDR-TB control; WHO Europe,
More informationTB Intensive Houston, Texas October 15-17, 2013
TB Intensive Houston, Texas October 15-17, 2013 MDR/XDR TB Barbara J. Seaworth, MD October 16, 2013 Barbara J. Seaworth, MD has the following disclosures to make: No conflict of interests No relevant financial
More informationCDC s Molecular Detection of Drug Resistance (MDDR) Service and Mycobacterium tuberculosis DST Model Performance Evaluation Program (MPEP)
CDC s Molecular Detection of Drug Resistance (MDDR) Service and Mycobacterium tuberculosis DST Model Performance Evaluation Program (MPEP) Beverly Metchock, DrPH, D(ABMM) Mycobacteriology Laboratory Branch/Division
More informationTHE NEW DR-TB NATIONAL POLICY AND STATE OF IMPLEMENTATION
1 THE NEW DR-TB NATIONAL POLICY AND STATE OF IMPLEMENTATION Dr. Norbert Ndjeka MD, DHSM (Wits), MMed(Fam Med) (MED), Dip HIV Man (SA) Director Drug-Resistant TB, TB and HIV National Department of Health
More informationTB Intensive San Antonio, Texas
TB Intensive San Antonio, Texas May 6 9, 2014 MDR/XDR TB Barbara Seaworth, MD May 9, 2014 Barbara Seaworth, MD has the following disclosures to make: No conflict of interests No relevant financial relationships
More informationMDR-TB is a manmade problem..it is costly, deadly, debilitating, and the biggest threat to our current TB control strategies 2
1 MDR-TB is a manmade problem..it is costly, deadly, debilitating, and the biggest threat to our current TB control strategies 2 1 India has the highest TB burden in the world 3 4 2 5 M. tuberculosis Resistance
More informationDrug Resistant Tuberculosis:
Drug Resistant Tuberculosis: Pearls and other Considerations John W. Wilson, MD Associate Professor of Medicine Division of Infectious Diseases Mayo Clinic, Rochester MN Mayo Clinic Center for Tuberculosis
More informationDR-TB PATIENT IDENTITY CARD
Ministry of Health Community Development Gender Elderly and Children National Tuberculosis and Leprosy Programme DR-TB 02 DR-TB Treatment Unit: DR-TB PATIENT IDENTITY CARD DR-TB Reg. Number: Date of registration:
More informationTB Intensive Houston, Texas. Multi-Drug Resistant (MDR) TB Barbara Seaworth, MD
TB Intensive Houston, Texas November 10-12, 12 2009 Multi-Drug Resistant (MDR) TB Barbara Seaworth, MD November 12, 2009 Multi-Drug Resistant (MDR) TB Updates November 12, 2009 Barbara J. Seaworth Professor
More informationCase 1 and Case 2. Case 1 3/23/2016
Case 1 and Deidra D. Parrish, MD, MPH&TM Nashville Metro Public Health Dept TB Symposium March 30, 2016 Case 1 27 yo Indian woman came to the US to join her husband three months prior to clinic visit.
More informationDrug resistant TB: The role of the laboratory
Drug resistant TB: The role of the laboratory 26 Oct 2012 Andrew Whitelaw NHSLS / UCT TB lab functions: Outline Resistance testing Genotypic Phenotypic Which tests are done when, and why Reporting of
More informationSummary of outcomes from WHO Expert Group Meeting on Drug Susceptibility Testing - PRELIMINARY -
Summary of outcomes from WHO Expert Group Meeting on Drug Susceptibility Testing PRELIMINARY 4 th Annual GLI meeting 17 April 2012 Fuad Mirzayev Laboratories, Diagnostics and Drug Resistance unit, Stop
More informationMulti-Drug and Extensively Drug Resistant Tuberculosis
Multi-Drug and Extensively Drug Resistant Tuberculosis Gwen A. Huitt, M.D., M.S. Professor, Department of Medicine Director, Adult Infectious Disease Care Unit National Jewish Health Disclosures None Tuberculosis
More informationExploring Novel Approaches to Shared TB Laboratory Services: California-Wisconsin Shared Services Pilot Study
Exploring Novel Approaches to Shared TB Laboratory Services: California-Wisconsin Shared Services Pilot Study Julie Tans-Kersten, MS, BS-MT (ASCP) Tuberculosis Laboratory Program Coordinator Wisconsin
More informationTreatment of MDR/XDR-TB. Short course chemotherapy for MDR-TB: practical issues. CHIANG Chen-Yuan MD, MPH, DrPhilos
Treatment of MDR/XDR-TB Short course chemotherapy for MDR-TB: practical issues CHIANG Chen-Yuan MD, MPH, DrPhilos Treatment strategies for MDR-TB Standardized treatment: drug resistance survey data from
More informationXDR TB: The Laboratory s Dilemma vs The Clinician s Dilemma
XD TB: The Laboratory s Dilemma vs The Clinician s Dilemma Barbara J. Seaworth, MD, FIDSA, FACP, Heartland National TB Center, San Antonio, TX Kenneth Jost, Jr., M(ASCP) Laboratory Services Section, Texas
More informationMDR-TB drugs per WHO guidelines
New antituberculous agents for drug-resistant resistant TB Symposium Belgian Society of Infectiology and Clinical Microbiology November 9 Jens Van Roey, MD - Tibotec Definitions MDR-TB multidrug resistance
More informationManagement of MDR and XDR TB Prof. Martin Boeree
Management of MDR and XDR TB 1, MD, PhD Associate Professor Consultant Respiratory Medicine Department of Lung Diseases Radboud University Nijmegen Medical Centre TB Referral Hospital Dekkerswald Nijmegen,
More informationTB New Drugs, Shorter Courses
TB New Drugs, Shorter Courses Brian Chong John Hunter Hospital, Newcastle NSW Talk supervisor: Chris Coulter Disclosures Unfortunately none 1 Current Situation In 2013, Australia had: 1,263 notified TB
More informationQuality of 2 nd line medicines for tuberculosis. Ms Lisa Hedman World Health Organization Department of Essential Medicines and Health Products
Quality of 2 nd line medicines for tuberculosis Ms Lisa Hedman World Health Organization Department of Essential Medicines and Health Products Case studies in medicines for tuberculosis Outline: Statistics
More informationTreatment for NTM: when how.and what next? Pr Claire Andréjak Respiratory and ICU Department University hospital, Amiens, France
Treatment for NTM: when how.and what next? Pr Claire Andréjak Respiratory and ICU Department University hospital, Amiens, France First step = To diagnose NTM disease One NTM positive sample NTM disease
More informationMultidrug resistant tuberculosis. Where next? Professor Peter D O Davies (Liverpool)
Multidrug resistant tuberculosis. Where next? Professor Peter D O Davies (Liverpool) DOTS + and LTBI New drugs for TB and the challenge of resistance talk plan 1. Epidemiology 2. Treatment 3. The MDRTB
More informationMDR treatment. Shanghai, May 2012 Arnaud Trébucq The Union
MDR treatment Shanghai, May 2012 Arnaud Trébucq The Union Why to diagnose MDR-TB? Outcome of SS+ new MDR-TB cases, treated with First Line TB (FLD) drugs Setting Success Died Fail LFFU Transf. Corea 20(56)
More informationNew drugs and regimens for treatment of drug-sensitive TB (DS-TB) Patrick
New drugs and regimens for treatment of drug-sensitive TB (DS-TB) Patrick Phillips Patrick.Phillips@ucsf.edu @PPJPhillips Outline Overview of regimen development strategies 1-3 year horizon: Ongoing phase
More informationThe New England Journal of Medicine THE TREATMENT OF MULTIDRUG-RESISTANT TUBERCULOSIS IN TURKEY
THE TREATMENT OF MULTIDRUG-RESISTANT TUBERCULOSIS IN TURKEY KEMAL TAHAOĞLU, M.D., TÜLAY TÖRÜN, M.D., TÜLIN SEVIM, M.D., GÜLIZ ATAÇ, M.D., ALTAN KIR, M.D., LEVENT KARASULU, M.D., IPEK ÖZMEN, M.D., AND NILÜFER
More informationIntroduction of Bedaquiline in the Philippines
Introduction of Bedaquiline in the Philippines 24th PhilCAT Annual Convention Crown Plaza Hotel August 18,2107 Vivian S. Lofranco, MD., PHSAE National Clinical Coordinator, BDQ MDR-TB is highly contagious
More informationDr Sharanjit Dhoot. Chelsea and Westminster Hospital, London. 18 th Annual Conference of the British HIV Association (BHIVA)
18 th Annual Conference of the British HIV Association (BHIVA) Dr Sharanjit Dhoot Chelsea and Westminster Hospital, London 18-20 April 2012, The International Convention Centre, Birmingham 18 th Annual
More informationEffects of Moxifloxacin PK-PD and drug interactions on its use in the Treatment of Tuberculosis(TB)
Effects of Moxifloxacin PK-PD and drug interactions on its use in the Treatment of Tuberculosis(TB) Session: Fanning the Flames of HIV and TB Cointeraction SA AIDS Conference-Durban ICC 13-15 June 2017
More informationCLINICAL USE OF AMINOGLYCOSIDES AND FLUOROQUINOLONES
CLINICAL USE OF AMINOGLYCOSIDES AND FLUOROQUINOLONES Douglas Black, Pharm.D. Associate Professor School of Pharmacy University of Washington dblack@u.washington.edu THE AMINOGLYCOSIDES: 1944-1975 Drug
More informationCLINICAL USE OF AMINOGLYCOSIDES AND FLUOROQUINOLONES THE AMINOGLYCOSIDES:
CLINICAL USE OF AMINOGLYCOSIDES AND FLUOROQUINOLONES Douglas Black, Pharm.D. Associate Professor School of Pharmacy University of Washington dblack@u.washington.edu THE AMINOGLYCOSIDES: 1944-1975 Drug
More informationTRANSPARENCY COMMITTEE
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 29 October 2014 GRANUPAS, gastro-resistant granules 30 sachets with a calibrated measuring spoon (CIP: 34009 278 801
More informationTreatment of Nontuberculous Mycobacterial Infections (NTM)
Treatment of Nontuberculous Mycobacterial Infections (NTM) Charles L. Daley, MD National Jewish Health University of Colorado, Denver Disclosures Investigator Insmed (inhaled liposomal amikacin) Advisory
More informationMGIT 2 nd LINE DRUG SUSCEPTIBILITY TESTING A personal experience
MGIT 2 nd LINE DRUG SUSCEPTIBILITY TESTING A personal experience Dr Johan Van Wyk MB.Ch.B, M.Med (Clin Path) Clinical Pathologist ibhayi Region, Eastern Cape GWYNETH PALTROW SHAKESPEARE IN LOVE 1998 PORT
More informationDisclosures. Principles of Antimicrobial Therapy. Obtaining an Accurate Diagnosis Obtain specimens PRIOR to initiating antimicrobials
Disclosures Principles of Antimicrobial Therapy None Lori A. Cox MSN, ACNP-BC, ACNPC, FCCM Penn State Hershey Medical Center Neuroscience Critical Care Unit Obtaining an Accurate Diagnosis Determine site
More informationCreating a global community for clinical drug repurposing and development. Leonard Sacks Center for drug evaluation and research FDA
Creating a global community for clinical drug repurposing and development Leonard Sacks Center for drug evaluation and research FDA Neglected tropical diseases 1) Repurposing and developing new drugs 2)
More informationIn Vitro Activities of Linezolid against Clinical Isolates of ACCEPTED
AAC Accepts, published online ahead of print on April 00 Antimicrob. Agents Chemother. doi:./aac.001-0 Copyright 00, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights
More informationPeriod of study: 12 Nov 2002 to 08 Apr 2004 (first subject s first visit to last subject s last visit)
Study Synopsis This file is posted on the Bayer HealthCare Clinical Trials Registry and Results website and is provided for patients and healthcare professionals to increase the transparency of Bayer's
More informationINCIDENCE OF BACTERIAL COLONISATION IN HOSPITALISED PATIENTS WITH DRUG-RESISTANT TUBERCULOSIS
INCIDENCE OF BACTERIAL COLONISATION IN HOSPITALISED PATIENTS WITH DRUG-RESISTANT TUBERCULOSIS 1 Research Associate, Drug Utilisation Research Unit, Nelson Mandela University 2 Human Sciences Research Council,
More informationBRUCELLOSIS BRUCELLOSIS. CPMP/4048/01, rev. 3 1/7 EMEA 2002
BRUCELLOSIS CPMP/4048/01, rev. 3 1/7 General points on treatment Four species are pathogenic to man: B. melitenis (acquired from goats), B. suis (pigs), B. abortus (cattle) and B. canis (dogs). The bacteria
More informationLinezolid: an effective, safe and cheap drug for patients failing multidrug-resistant tuberculosis treatment in India
Eur Respir J 2012; 39: 956 962 DOI: 10.1183/09031936.00076811 CopyrightßERS 2012 Linezolid: an effective, safe and cheap drug for patients failing multidrug-resistant tuberculosis treatment in India R.
More informationAppropriate antimicrobial therapy in HAP: What does this mean?
Appropriate antimicrobial therapy in HAP: What does this mean? Jaehee Lee, M.D. Kyungpook National University Hospital, Korea KNUH since 1907 Presentation outline Empiric antimicrobial choice: right spectrum,
More informationRisk Factors for Poor Outcomes in Patients with Multi-Drug Resistant Tuberculosis in South Korea
Hanyang Med Rev 2016;36:262-268 https://doi.org/10.7599/hmr.2016.36.4.262 pissn 1738-429X eissn 2234-4446 Original Article Risk Factors for Poor Outcomes in Patients with Multi-Drug Resistant Tuberculosis
More informationNon-Tuberculous Mycobacterial Pulmonary Disease Diagnosis and Management Jakko van Ingen, MD, PhD
Non-Tuberculous Mycobacterial Pulmonary Disease (NTM-PD) 1 Radbound University Nihmegen Medical Center Milestones in NTM research 1980s: Nodular bronchiectatic lung disease Lady Windermere syndrome 1882-1890
More informationTb : Recent recommendation. Dr.Ketan Shah
Tb : Recent recommendation Dr.Ketan Shah Tbc : Clinician If you think It is easy to diagnose : u r not good clinician It is difficult to diagnose :U r not alone doctor to think this 6/22/2015 Ketan Shah
More informationECHO: Management of URIs. Charles Krasner, M.D. Sierra NV Veterans Affairs Hospital University of NV, Reno School of Medicine October 16, 2018
ECHO: Management of URIs Charles Krasner, M.D. Sierra NV Veterans Affairs Hospital University of NV, Reno School of Medicine October 16, 2018 Infectious causes of URIs change over time Most ARIs are viral
More informationCase Presentations: Non Responding TB Dr. Manoj Yadav
Case Presentations: Non Responding TB Dr. Manoj Yadav mbbs, dtcd, dnb (resp. dis.) Consultant Pulmonologist Kailash Hospital, Kailash Complex Near Mahadev Temple, Productivity Road Vadodara 390007 :: Phone:
More informationAntibiotic stewardship in long term care
Antibiotic stewardship in long term care Shira Doron, MD Associate Professor of Medicine Division of Geographic Medicine and Infectious Diseases Tufts Medical Center Boston, MA Consultant to Massachusetts
More informationAntibiotics & Common Infections: Stewardship, Effectiveness, Safety & Clinical Pearls. Welcome We will begin shortly.
Antibiotics & Common Infections: Stewardship, Effectiveness, Safety & Clinical Pearls Welcome We will begin shortly. The Canadian Pharmacists Association is pleased to be collaborating with the following
More informationTuberculosis in 2017: Searching for new solutions in the face of new challenges
Tuberculosis in 2017: Searching for new solutions in the face of new challenges 6th TB Symposium Ministry of Health of the Republic of Belarus, Republican Scientific and Practical Center for Pulmonology
More informationDefine evidence based practices for selection and duration of antibiotics to treat suspected or confirmed neonatal sepsis
GLOBAL AIM: Antibiotic Stewardship Perinatal Quality Improvement Teams (PQITs) will share strategies and lessons learned to develop potentially better practices and employ QI methodologies to establish
More informationAntimicrobial Stewardship in the Long Term Care and Outpatient Settings. Carlos Reyes Sacin, MD, AAHIVS
Antimicrobial Stewardship in the Long Term Care and Outpatient Settings Carlos Reyes Sacin, MD, AAHIVS Disclosure Speaker and consultant in HIV medicine for Gilead and Jansen Pharmaceuticals Objectives
More informationANTHRAX. INHALATION, INTESTINAL and CUTANEOUS ANTHRAX
INHALATION, INTESTINAL and CUTANEOUS ANTHRAX CPMP/4048/01, rev. 3 1/7 General points on treatment Anthrax is an acute infectious disease caused by Bacillus anthracis, that may be infecting man via cutaneous
More informationCurricular Components for Infectious Diseases EPA
Curricular Components for Infectious Diseases EPA 1. EPA Title Promoting antimicrobial stewardship based on microbiological principles 2. Description of the A key role for subspecialists is to utilize
More informationPlease distribute a copy of this information to each provider in your organization.
HEALTH ADVISORY TO: Physicians and other Healthcare Providers Please distribute a copy of this information to each provider in your organization. Questions regarding this information may be directed to
More informationStaph Cases. Case #1
Staph Cases Lisa Winston University of California, San Francisco San Francisco General Hospital Case #1 A 60 y.o. man with well controlled HIV and DM presents to clinic with ten days of redness and swelling
More informationBRUCELLOSIS. Morning report 7/11/05 Andy Bomback
BRUCELLOSIS Morning report 7/11/05 Andy Bomback Also called undulant, Mediterranean, or Mata fever, brucellosis is an acute and chronic infection of the reticuloendothelial system gram negative facultative
More information4/3/2017 CLINICAL PEARLS: UPDATES IN THE MANAGEMENT OF NOSOCOMIAL PNEUMONIA DISCLOSURE LEARNING OBJECTIVES
CLINICAL PEARLS: UPDATES IN THE MANAGEMENT OF NOSOCOMIAL PNEUMONIA BILLIE BARTEL, PHARMD, BCCCP APRIL 7 TH, 2017 DISCLOSURE I have had no financial relationship over the past 12 months with any commercial
More informationUniversity of Groningen. Tuberculosis and its sequelae Akkerman, Onno
University of Groningen Tuberculosis and its sequelae Akkerman, Onno IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document
More informationOral antibiotics are not always straight forward
Oral antibiotics are not always straight forward OPAT Regional Workshop 1 st May 2018 Fiona Robb, Antimicrobial Pharmacist NHS Greater Glasgow & Clyde Introduction Describe NHS GGC s Oral vs IV Antibiotics
More informationInteractive session: adapting to antibiogram. Thong Phe Heng Vengchhun Felix Leclerc Erika Vlieghe
Interactive session: adapting to antibiogram Thong Phe Heng Vengchhun Felix Leclerc Erika Vlieghe Case 1 63 y old woman Dx: urosepsis? After 2 d: intermediate result: Gram-negative bacilli Empiric antibiotic
More informationNurse Prescribing: Key Principles and Developments. Elissa Ladd, PhD, FNP-BC MGH Institute of Health Professions Boston, Massachusetts USA
Nurse Prescribing: Key Principles and Developments Elissa Ladd, PhD, FNP-BC MGH Institute of Health Professions Boston, Massachusetts USA No disclosures to report Objectives: 1) To provide an overview
More information10/13/14. Low: not well absorbed. Good: [blood and tissue] < than if given IV. High: > 90% absorption orally
Low: not well absorbed PO agent not for serious infection nitrofurantoin Good: [blood and tissue] < than if given IV [Therapeutic] in excess of [effective] eg. cephalexin High: > 90% absorption orally
More informationTreatment of Slowly Growing NTM Infections
Treatment of Slowly Growing NTM Infections Charles L. Daley, MD National Jewish Health University of Colorado, Denver Disclosures Investigator Insmed (inhaled liposomal amikacin) Advisory Committee Insmed
More informationCLINICAL PROTOCOL FOR COMMUNITY ACQUIRED PNEUMONIA. SCOPE: Western Australia. CORB score equal or above 1. All criteria must be met:
CLINICAL PROTOCOL F COMMUNITY ACQUIRED PNEUMONIA SCOPE: Western Australia All criteria must be met: Inclusion Criteria Exclusion Criteria CB score equal or above 1. Mild/moderate pneumonia confirmed by
More informationPharmacokinetic & Pharmadynamic of Once Daily Aminoglycosides (ODA) and their Monitoring. Janis Chan Pharmacist, UCH 2008
Pharmacokinetic & Pharmadynamic of Once Daily Aminoglycosides (ODA) and their Monitoring Janis Chan Pharmacist, UCH 25-4-2008 2008 Aminoglycosides (AG) 1. Gentamicin 2. Amikacin 3. Streptomycin 4. Neomycin
More informationOutlines. Introduction Prevalence Resistance Clinical presentation Diagnosis Management Prevention Case presentation Achievements
Amal Meas Al-Anizi, PharmD Candidate KSU, Infectious Disease Rotation 2014 Outlines Introduction Prevalence Resistance Clinical presentation Diagnosis Management Prevention Case presentation Achievements
More informationHost, Syndrome, Bug, Drug: Introducing 2 Frameworks to Approach Infectious Diseases Cases with an Antimicrobial Stewardship Focus
Host, Syndrome, Bug, Drug: Introducing 2 Frameworks to Approach Infectious Diseases Cases with an Antimicrobial Stewardship Focus Montana ACP Meeting 2018 September 8, 2018 Staci Lee, MD, MEHP Billings
More informationTularemia. Information for Health Care Providers. Physicians D Nurses D Laboratory Personnel D Infection Control Practitioners
Tularemia Information for Health Care Providers Physicians D Nurses D Laboratory Personnel D Infection Control Practitioners Tularemia Caused by Francisella tularensis, a small, pleomorphic, gram-negative
More information1. The preferred treatment option for an initial UTI episode in a 22-year-old female patient
1 Chapter 79, Self-Assessment Questions 1. The preferred treatment option for an initial UTI episode in a 22-year-old female patient with normal renal function is: A. Trimethoprim-sulfamethoxazole B. Cefuroxime
More informationDATA COLLECTION SECTION BY FRONTLINE TEAM. Patient Identifier/ Medical Record number (for facility use only)
Assessment of Appropriateness of ICU Antibiotics (Patient Level Sheet) **Note this is intended for internal purposes only. Please do not return to PQC.** For this assessment, inappropriate antibiotic use
More informationAntimicrobial Update. Alison MacDonald Area Antimicrobial Pharmacist NHS Highland April 2018
Antimicrobial Update Alison MacDonald Area Antimicrobial Pharmacist NHS Highland alisonc.macdonald@nhs.net April 2018 Starter Questions Setting the scene... What if antibiotics were no longer effective?
More informationAntibiotics in the trenches: An ER Doc s Perspective
Antibiotics in the trenches: An ER Doc s Perspective Peter Currie, MD Medical Director for Quality Emergency Physicians Professional Association (EPPA) Agenda Emergency Medicine Specific Disease Processes
More information11/22/2016. Antimicrobial Stewardship Update Disclosures. Outline. No conflicts of interest to disclose
Antimicrobial Stewardship Update 2016 APIC-CI Conference November 17 th, 2016 Jay R. McDonald, MD Chief, ID Section VA St. Louis Health Care System Assistant Professor of medicine Washington University
More informationExtensively Drug-Resistant Tuberculosis in South Korea: Risk Factors and Treatment Outcomes among Patients at a Tertiary Referral Hospital
MAJOR ARTICLE Extensively Drug-Resistant Tuberculosis in South Korea: Risk Factors and Treatment Outcomes among Patients at a Tertiary Referral Hospital Christie Y. Jeon, 1,2,a Soo Hee Hwang, 5,a Jin Hong
More informationLefamulin Evaluation Against Pneumonia (LEAP 1) Phase 3 Topline Results. September 18, 2017
Lefamulin Evaluation Against Pneumonia (LEAP 1) Phase 3 Topline Results September 18, 2017 Safe Harbor and Disclaimer Any statements in this presentation about future expectations, plans and prospects
More informationETX2514SUL (sulbactam/etx2514) for the treatment of Acinetobacter baumannii infections
ETX2514SUL (sulbactam/etx2514) for the treatment of Acinetobacter baumannii infections Robin Isaacs Chief Medical Officer, Entasis Therapeutics Dr. Isaacs is a full-time employee of Entasis Therapeutics.
More informationCurrent Status of Fluoroquinolone Use for Treatment of Tuberculosis in a Tertiary Care Hospital in Korea
ORIGINAL ARTICLE https://doi.org/10.4046/trd.2017.80.2.143 ISSN: 1738-3536(Print)/2005-6184(Online) Tuberc Respir Dis 2017;80:143-152 Current Status of Fluoroquinolone Use for Treatment of Tuberculosis
More informationThe challenge of managing extensively drug-resistant tuberculosis at a referral hospital in the state of São Paulo, Brazil: a report of three cases
J Bras Pneumol. 2015;41(6):554-559 http://dx.doi.org/10.1590/s1806-37562015000000299 CASE REPORT The challenge of managing extensively drug-resistant tuberculosis at a referral hospital in the state of
More informationAntibiotic Prophylaxis in Spinal Surgery Antibiotic Guidelines. Contents
Antibiotic Prophylaxis in Spinal Antibiotic Guidelines Classification: Clinical Guideline Lead Author: Antibiotic Steering Committee Additional author(s): Authors Division: DCSS & Tertiary Medicine Unique
More informationUpdate on Fluoroquinolones. Charles Krasner, M.D. June 16, 2016 Antibiotic Stewardship Program -ECHO
Update on Fluoroquinolones Charles Krasner, M.D. June 16, 2016 Antibiotic Stewardship Program -ECHO Potential fluoroquinolone side-effects Increased risk, greater than with most other antibiotics, for
More informationTreatment of Respiratory Tract Infections Prof. Mohammad Alhumayyd Dr. Aliah Alshanwani
Treatment of Respiratory Tract Infections Prof. Mohammad Alhumayyd Dr. Aliah Alshanwani 30-1-2018 1 Objectives of the lecture At the end of lecture, the students should be able to understand the following:
More informationOnline data supplement
Online data supplement Title: Fluoroquinolone therapy for the prevention of multi-drug resistant tuberculosis in contacts: a cost-effectiveness analysis Authors: Gregory J Fox Olivia Oxlade Dick Menzies
More informationClinical Manifestations and Treatment of Plague Dr. Jacky Chan. Associate Consultant Infectious Disease Centre, PMH
Clinical Manifestations and Treatment of Plague Dr. Jacky Chan Associate Consultant Infectious Disease Centre, PMH Update of plague outbreak situation in Madagascar A large outbreak since 1 Aug 2017 As
More informationMultidrug resistant tuberculosis treatment in the Indian private sector: Results from a tertiary referral private hospital in Mumbai
Original Article Multidrug resistant tuberculosis treatment in the Indian private sector: Results from a tertiary referral private hospital in Mumbai Zarir F. Udwadia, Gautam Moharil Department of Pulmonology,
More informationPharmacokinetics. Absorption of doxycycline is not significantly affected by milk or food, but coadministration of antacids or mineral supplements
Pharmacokinetics. Absorption of doxycycline is not significantly affected by milk or food, but coadministration of antacids or mineral supplements should be avoided. PDR Drug Summaries are concise point-of-care
More information3/23/2017. Kathryn G. Smith, PharmD PGY1 Pharmacy Resident Via Christi Hospitals Wichita, Inc. Kathryn G. Smith: Nothing to disclose
Kathryn G. Smith, PharmD PGY1 Pharmacy Resident Via Christi Hospitals Wichita, Inc Kathryn G. Smith: Nothing to disclose Describe the new updates and rationale for them Relay safety concerns with use of
More informationSection 6.2.4: Antituberculosis Medicines Application for moving streptomycin to complementary list
Section 6.2.4: Antituberculosis Medicines Application for moving streptomycin to complementary list Stop TB Department World Health Organization Summary According to the recent guideline published in 2010
More information